Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

129.46 +0.46 (+0.36%)
Streaming Delayed Price Updated: 11:51 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,734
Open 129.19
Bid (Size) 128.89 (100)
Ask (Size) 129.86 (100)
Prev. Close 129.00
Today's Range 128.49 - 132.53
52wk Range 20.20 - 151.18
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
From Palvella Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+29.1%
+29.1%
1 Month
+2.7%
+2.7%
3 Month
+28.8%
+28.8%
6 Month
+69.9%
+69.9%
1 Year
+429.7%
+429.7%

More News

Read More
News headline image
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Pricing of Upsized Public Offering
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Proposed Public Offering
From Palvella Therapeutics Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
From Palvella Therapeutics Inc.
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
What is the current price of Palvella Therapeutics, Inc. - Common Stock?
The current price of Palvella Therapeutics, Inc. - Common Stock is 129.46
When was Palvella Therapeutics, Inc. - Common Stock last traded?
The last trade of Palvella Therapeutics, Inc. - Common Stock was at 04/14/26 11:51 AM ET
What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 12.81B
How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
Palvella Therapeutics, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.